Buy tech sell-off, Wedbush’s Ives says: ’this is a 1996 moment, not 1999’
POMDOCTOR LIMITED, a China-based online medical services platform for chronic diseases, priced its initial public offering at $4.00 per American Depositary Share, the company announced.
The offering consists of 5,000,004 ADSs, with six ADSs representing one Class A ordinary share. The company expects to receive approximately $20.0 million in gross proceeds before deducting underwriting discounts and expenses.
The ADSs received approval for listing on the Nasdaq Global Market under ticker symbol "POM" (POM) and began trading October 8, 2025. The offering is expected to close on or about October 9, 2025.
POMDOCTOR has granted underwriters an option to purchase up to an additional 750,000 ADSs within 45 days from the final prospectus date at the public offering price, less underwriting discounts. Joseph Stone Capital, LLC serves as the underwriter for the offering.
The Securities and Exchange Commission declared the company’s Form F-1 registration statement effective September 30, 2025. The registration statement carries file number 333-285771.
According to the company’s statement, POMDOCTOR operates as an online medical services platform focusing on chronic disease management and pharmaceutical services in China. The platform connects patients with doctors and pharmaceutical products through internet hospital and pharmaceutical supply chain operations.
The company states it ranked sixth in China’s internet hospital market based on the number of contracted doctors in 2022, according to Frost & Sullivan data.